Avalo Therapeutics (NASDAQ:AVTX) Earns Outperform Rating from Analysts at Leerink Partners

Equities research analysts at Leerink Partners initiated coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a note issued to investors on Monday,Benzinga reports. The firm set an “outperform” rating and a $38.00 price target on the stock. Leerink Partners’ target price would suggest a potential upside of 101.70% from the company’s previous close.

Several other brokerages have also issued reports on AVTX. Citizens Jmp dropped their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Wedbush decreased their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. HC Wainwright decreased their price target on shares of Avalo Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Finally, BTIG Research reiterated a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research note on Tuesday, June 16th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $45.80.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $18.84 on Monday. The business’s 50 day moving average price is $16.34 and its 200-day moving average price is $16.07. Avalo Therapeutics has a 1 year low of $4.61 and a 1 year high of $24.27. The firm has a market capitalization of $990.42 million, a price-to-earnings ratio of -3.45 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. On average, sell-side analysts expect that Avalo Therapeutics will post -2.58 earnings per share for the current year.

Insider Activity

In other news, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $13.23, for a total value of $111,886.11. Following the completion of the sale, the chief financial officer directly owned 423 shares in the company, valued at $5,596.29. This represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares in the company, valued at approximately $73,297.78. This represents a 95.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 93,428 shares of company stock worth $1,762,722 over the last three months. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AVTX. PFS Partners LLC grew its position in shares of Avalo Therapeutics by 100.0% in the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after purchasing an additional 1,000 shares in the last quarter. Geode Capital Management LLC lifted its position in Avalo Therapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after buying an additional 2,648 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock worth $384,000 after buying an additional 5,280 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics during the third quarter worth $143,000. Finally, Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics during the second quarter worth $56,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.